Please reload

Recent Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

August 3, 2018

1/2
Please reload

Featured Posts

Sage Group Advises APR on InLicensing and Acquisition of Novel Pharma Products

September 2, 2016

 

ABOUT APR

Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss developer of specialty healthcare products, with over 20 years of experience. APR has a proven track record in successfully developing and marketing novel products in various therapeutic areas on a global basis. APR identifies, in-licenses, develops (using 'state-of-the-art' technology, innovative formulations, dosage forms and delivery systems) and then commercializes through partners, science driven, branded products with unique selling points designed to address patient needs in niche or rare therapy areas.

 

APR’s business strategy starts from an understanding of the needs of various stakeholders and it then translates into product development the best products that address such needs. Product development is not restrained by the use of APR’s technologies. APR searches for the most innovative technologies available in the marketplace and it enters into co-development partnership with the originators of the technology for the development of the products. Finished products, and not technologies, are APR’s main focus.

 

APR OBJECTIVES

APR seeks to develop mutually profitable relationships with companies around the globe based on its partner’s products and technologies coupled with APR’s technological, developmental and regulatory expertise. By leveraging the combination of APR’s and its partner’s assets and capabilities, APR plans to continues its successful track record of out-licensing the resulting unique products. The ideal product is one regulated under the FDA’s 505(b2) pathway with a distinctive USP (Unique Selling Proposition), under development and/or fully developed, with a maximum 3-year time to market and potentially revenues in the US in any of the following broad fields.

  • Wound management

  • Niche pain and inflammation indications

  • Gastrointestinal

  • Rare diseases

  • Supportive care

 

Benefits of working with APR

APR employs a proven business model offering high potential and low risk for its partners. This includes:

  • Strong network of international partners in 70 markets

  • Strong formulation knowhow and ability to develop innovative dosage forms

  • Experienced management team.

  • Strong financial backers

  • Centrally managed operations with focus on in-house and high quality core competencies

  • Global development, regulatory and licensing capabilities

  • Committed to patients and partners.

 

Share on Facebook
Share on Twitter
Please reload

Follow Us
Please reload

Search By Tags